Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2013

View Archived Issues

Clinical data for AMP-224 presented at AACR meeting

Polymorphisms in NPY and IL1B genes identified as risk factors for vitiligo

FDA approves Sitavig for labial herpes

Innovative 3D renal tissue model developed to investigate human disease and toxicity

IMCgp-100 well tolerated in patients with advanced melanoma

VAL-201 shows promise in animal models of prostate and breast cancer

Achillion begins phase II HCV study of sovaprevir and ACH-3102

Allergan receives complete response letter for Levadex NDA

Ablynx presents in vitro and in vivo data for novel anti-c-Met Nanobody

Merck & Co. synthesizes new FSH-R antagonists for gynecological disorders

Roche discloses novel eIF4E inhibitors for cancer

New JAK1/JAK2 inhibitors divulged by Merck & Co.

Boehringer Ingelheim patents new DPPI inhibitors

Bayer prepares new Mnk1 inhibitors for hyperproliferative diseases

Researchers at GlaxoSmithKline synthesize new mTOR inhibitors

FDA grants Charleston Laboratories' request for pre-IND meeting

Galapagos expands phase IIb trial of GLPG-0634 in rheumatoid arthritis

Clinical trial application submitted to RAC for TT-034

Eisai receives marketing authorization in Japan for vascular embolization device Dc Bead

Nymox's candidate for BPH shows promising sexual function profile in new study

Collegium Pharmaceutical completes study on Oxycodone DETERx

Neuralstem receives FDA approval to conduct phase II stem cell trial for ALS

Taisho seeks Japanese approval of luseogliflozin for type 2 diabetes

Omeros files orphan drug application for OMS-721

Santarus and Pharming report submission of Ruconest BLA to FDA

FDA advisory committee votes in favor of Breo Ellipta for COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...